BMS Sues Amgen Over Patents for Cancer Treatment Opdivo

Bristol Myers Squibb (BMS) has filed a patent suit against Amgen in an ongoing eventful year for biosimilar disputes. The lawsuit concerns Opdivo, a cancer treatment developed by BMS.

According to the source, this is just one of several high-profile patent cases that have emerged in 2026. Other notable events include a leaked European Commission standardization regulation and a ruling on AI and obviousness.

The lawsuit between BMS and Amgen adds to the growing list of patent disputes in the biosimilar space. This development has significant implications for companies involved in the production and distribution of biosimilars, which are cheaper alternatives to patented biologics.